HAMP and sickle cell disease: Furthermore, hepcidin analogues or mimetics have entered trials for the treatment of iron-related disorders, including hereditary haemochromatosis, β-thalassaemia, sickle cell disease, and myelodysplastic syndrome, which supports the broad applicability and multifunctionality of this type of therapeutic replacement, either alone or as an adjuvant to phlebotomy, erythrocytapheresis or chelation therapies [13,14,15,16].